Skip to main content
SpringerLink
Log in

MiR-96-5p is an oncogene in lung adenocarcinoma and facilitates tumor progression through ARHGAP6 downregulation

  • Human Genetics • Original Paper
  • Published:
Journal of Applied Genetics Aims and scope Submit manuscript

Abstract

Accumulating investigations illustrated that miRNA acts as a key regulator in tumor progression, whereas regulatory role of miR-96-5p in lung adenocarcinoma (LUAD) is warranted. Thus, we sought to probe mechanism of miR-96-5p in this disease. Through bioinformatics analysis, miR-96-5p level in normal tissue and LUAD tissue in TCGA database were obtained. Meanwhile, mRNA expression dataset was analyzed to obtain downregulated mRNAs binding to miR-96-5p. qRT-PCR assessed miR-96-5p and ARHGAP6 mRNA in LUAD. Western blot assessed protein level of ARHGAP6 in LUAD. Dual-luciferase reporter gene detection verified targeting relationship of miR-96-5p and ARHGAP6. Biological functional experiments such as CCK-8, colony formation, scratch healing, and Transwell assessed cell proliferation, migration, and invasion. MiR-96-5p was overexpressed, which fostered LUAD cell proliferation, migration, and invasion. ARHGAP6 was downregulated in LUAD and targeted by miR-96-5p. ARHGAP6 upregulation prominently restored promotion of miR-96-5p on cell progression. MiR-96-5p could stimulate LUAD progression through targeting ARHGAP6. This study generates a novel direction and lays a theoretical basis for targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The data used to support the findings of this study are included within the article. The data and materials in the current study are available from the corresponding author on reasonable request.

References

  • Mostafa AA, Morris DG (2014) Immunotherapy for lung cancer: has it finally arrived? Front Oncol 4:288. https://doi.org/10.3389/fonc.2014.00288

  • Ferlay J et al (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144:1941–1953. https://doi.org/10.1002/ijc.31937

  • Devarakonda S, Morgensztern D, Govindan R (2015) Genomic alterations in lung adenocarcinoma. Lancet Oncol 16:e342-351. https://doi.org/10.1016/S1470-2045(15)00077-7

  • Antonia SJ (2019) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer Reply. N Engl J Med 380:990. https://doi.org/10.1056/NEJMc1900407

  • Kanodra NM, Silvestri GA, Tanner NT (2015) Screening and early detection efforts in lung cancer. Cancer 121:1347–1356. https://doi.org/10.1002/cncr.29222

  • Sanada, H. et al (2019) Involvement of dual strands of miR-143 (miR-143–5p and miR-143–3p) and their target oncogenes in the molecular pathogenesis of lung adenocarcinoma. Int J Mol Sci 20, https://doi.org/10.3390/ijms20184482

  • Greenawalt EJ et al (2019) Targeting of SGK1 by miR-576-3p inhibits lung adenocarcinoma migration and invasion. Mol Cancer Res 17:289–298. https://doi.org/10.1158/1541-7786.MCR-18-0364

  • Sun Y et al (2016) miR-297 acts as an oncogene by targeting GPC5 in lung adenocarcinoma. Cell Prolif 49:636–643. https://doi.org/10.1111/cpr.12288

  • Zhang H, Chen R, Shao J (2020) MicroRNA-96-5p facilitates the viability, migration, and invasion and suppresses the apoptosis of cervical cancer cells bynegatively modulating SFRP4. Technol Cancer Res Treat 19:1533033820934132. https://doi.org/10.1177/1533033820934132

  • Wang B, Liu X, Meng X (2020) miR-96-5p enhances cell proliferation and invasion via targeted regulation of ZDHHC5 in gastric cancer. Biosci Rep 40(4):BSR20191845

    Article  CAS  Google Scholar 

  • Ding L et al (2021) AIMP3 inhibits cell growth and metastasis of lung adenocarcinoma through activating a miR-96-5p-AIMP3-p53 axis. J Cell Mol Med 25:3019–3030. https://doi.org/10.1111/jcmm.16344

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tang H, Liu Y, Cheng W, He Z, Zhou N (2019) microRNA-96-5p induces the epithelial-mesenchymal transition to promote the metastasis of hepatocellular carcinoma by post-transcriptionally downregulating Talin 1. Int J Clin Exp Pathol 12:1897–1908

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhou Y et al (2019) MicroRNA-195 suppresses the progression of lung adenocarcinoma by directly targeting apelin. Thorac Cancer 10:1419–1430. https://doi.org/10.1111/1759-7714.13087

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang J et al (2020) miR-15b enhances the proliferation and migration of lung adenocarcinoma by targeting BCL2. Thorac Cancer 11:1396–1405. https://doi.org/10.1111/1759-7714.13382

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Prakash SK et al (2000) Functional analysis of ARHGAP6, a novel GTPase-activating protein for RhoA. Hum Mol Genet 9:477–488. https://doi.org/10.1093/hmg/9.4.477

    Article  CAS  PubMed  Google Scholar 

  • Wu Y, Xu M, He R, Xu K, Ma Y (2019) ARHGAP6 regulates the proliferation, migration and invasion of lung cancer cells. Oncol Rep 41:2281–2888. https://doi.org/10.3892/or.2019.7031

    Article  CAS  PubMed  Google Scholar 

  • Chen WX et al (2019) Bioinformatics analysis of potential therapeutic targets among ARHGAP genes in breast cancer. Oncol Lett 18:6017–6025. https://doi.org/10.3892/ol.2019.10949

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li J, Liu Y, Yin Y (2016) Inhibitory effects of Arhgap6 on cervical carcinoma cells. Tumour Biol 37:1411–1425. https://doi.org/10.1007/s13277-015-4502-z

    Article  CAS  PubMed  Google Scholar 

  • Li P, Lv H, Xu M, Zang B, Ma Y (2020) ARHGAP6 promotes apoptosis and inhibits glycolysis in lung adenocarcinoma through STAT3 signaling pathway. Cancer Manag Res 12:9665–9678. https://doi.org/10.2147/CMAR.S257759

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

1. This study was supported by the funds from 2020 Zhejiang Medical and Health Science and Technology Program (above item). Funds: 2020KY053.

2. This study was supported by the funds from Zhejiang Lung Cancer center.

Author information

Authors and Affiliations

  1. Department of Cardiothoracic Surgery, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), NO. 158 Shangtang Road, Xiacheng District, Hangzhou, 310014, Zhejiang, China

    Zhifang Liu, Yong Cui, Shuwei Wang, Changhao Wu, Fuyang Mei, Erlei Han, Zhibin Hu & Bing Zhou

Authors
  1. Zhifang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuwei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Changhao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fuyang Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Erlei Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhibin Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bing Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZF contributed to the study design. BZ conducted the literature search. YC and SW acquired the data. CH wrote the article. FY performed data analysis. EL drafted. ZF and ZB revised the article and gave the final approval of the version to be submitted. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Bing Zhou.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors consent to submit the manuscript for publication.

Conflict of interest

The authors declare no competing interests.

Additional information

Communicated by Michal Witt

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Z., Cui, Y., Wang, S. et al. MiR-96-5p is an oncogene in lung adenocarcinoma and facilitates tumor progression through ARHGAP6 downregulation . J Appl Genetics 62, 631–638 (2021). https://doi.org/10.1007/s13353-021-00652-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13353-021-00652-1

Keywords

Search

Navigation